Belantamab mafodotin combination therapies in early RRMM скачать в хорошем качестве

Belantamab mafodotin combination therapies in early RRMM

This discussion was supported by GSK. All content was developed independently by the steering committee in collaboration with SES. Funders were allowed no influence on the content of the discussion.   During the Multiple Myeloma Hub Steering Committee Meeting in November 2024, key opinion leaders met to discuss belantamab mafodotin (belamaf) combination therapies for early relapsed/refractory multiple myeloma (RRMM), with a focus on patient-specific considerations in developing personalized treatment plans. The discussion included emerging data from recent clinical trials, the integration of novel therapies such as BCMA-directed therapies, and the challenges when selecting appropriate regimens based on patient and disease characteristics. The meeting opened with a presentation by María-Victoria Mateos on the safety, efficacy, and positioning of novel combinations of belantamab-based regimens, BCMA CAR-T therapies, and bispecific monoclonal antibodies in various patient scenarios. Following this presentation, Mateos chaired a Q&A session featuring Sagar Lonial, Paul Richardson, Shaji Kumar, Hermann Einsele, Heinz Ludwig, Bruno Paiva, Meral Beksaç, Elena Zamagni, Sonja Zweegman, Morie Gertz, and Miles Prince.